Business
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nRevenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data\n\n\nRaises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25%\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025.\n\n\nSecond Quarter 2025 Financial Highlights\n\n\nFor the three-month period ended June 30, 2025, as compared to the same period of 2024:\n\n\n\nReported total revenue of $232.1 million, an increase of 31%, driven by:\n\n\nOncology revenue of $158.7 million, an increase of 22%, and approximately 64,000 oncology tests, an increase of 30%\n\n\n\nScreening revenue of $14.8 million, and approximately 16,000 Shield screening tests\n\n\n\nBiopharma & Data revenue of $56.0 million, an increase of 28%\n\n\n\n\n\n\nGenerated non-GAAP gross margin of 66%, compared to 60% in the second quarter of 2024\n\n\n\nGuardant360 Tissue average selling price increased to approximately $2,000, achieving 2028 target three years ahead of schedule\n\n\n\nRecent Operating Highlights\n\n\n\nIntroduced 11 groundbreaking Smart Liquid Biopsy applications for Guardant360 Liquid that greatly expands the differentiated clinical utility for therapy selection\n\n\n\nSubmitted Reveal breast cancer package to MolDx for Medicare reimbursement following publication in ESMO Open\n\n\n\nPublished RADIOHEAD immuno-oncology monitoring study for Reveal in Cancer Research Communications, with data from 521 stage IV pan-cancer patients\n\n\n\nExpanded Oncology offerings with launches of Guardant Hereditary Cancer Testing and a suite of immunohistochemistry tests\n\n\n\nShield included in the updated National Comprehensive Cancer Network, or NCCN, colorectal cancer screening guidelines\n\n\n\nEnrollment commenced for NCI Vanguard study for Shield Multi-Cancer Detection (MCD)\n\n\n\nShield MCD granted Breakthrough Device Designation from the FDA\n\n\n\nShield named a winner of Fast Company’s 2025 World Changing Ideas Awards\n\n\n\n“Q2 was another exceptional quarter for Guardant and we were able to increase our 2025 revenue guidance yet again. We saw especially strong performance from Guardant360 Liquid, where year-over-year growth accelerated for the fourth consecutive quarter,” said Helmy ...